UroGen Pharma Ltd. announced that Peter P. Pfreundschuh has been appointed as Chief Financial Officer (CFO) effective August 20, 2018. Mr. Pfreundschuh brings to UroGen more than two decades of executive leadership experience in life sciences. Stephen Mullennix, who has served as UroGen Interim CFO since June 2018, will continue in his role as the Company Chief Operating Officer (COO). Mr. Pfreundschuh previously served as the CFO of Sucampo Pharmaceuticals Inc. where he played a critical role in its recent acquisition by Mallinckrodt for $1.2 Billion in February 2018. Prior to joining Sucampo, he was Executive Vice President of Finance and CFO of Immunomedics Inc.